Navigation Links
Zimmer Holdings Issues Clarification Regarding NexGen Knee System
Date:7/14/2008

WARSAW, Ind., July 14 /PRNewswire-FirstCall/ -- Zimmer Holdings, Inc. (NYSE: ZMH; SWX: ZMH) statement:

A news story earlier this morning incorrectly stated that Zimmer's NexGen(R) knee implant had been recalled. In fact, the recall notification cited refers only to a surgical instrument used for minimally invasive surgeries (MIS) and not the implant system itself. The Company says that the recall is isolated to a single surgical instrument and that additional instrumentation options are available. The Company does not expect this instrument recall will have a material impact on sales.

Zimmer Safe Harbor Statement

This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management's beliefs and assumptions made by management. Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," and "seeks" or the negative of such terms or other variations on such terms or comparable terminology. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially. These risks and uncertainties include, but are not limited to, our compliance with the Deferred Prosecution Agreement through March 2009 and the Corporate Integrity Agreement through 2012, the impact of our enhanced healthcare compliance global initiatives and business practices on our relationships with customers and consultants, our market share and our overall financial performance, the success of our quality initiatives, the outcome of the informal investigation by the U.S. Securities and Exchange Commission into Foreign Corrupt Practices Act matters announced in October 2007, price and product competition, rapid technological development, demographic changes, dependence on new product development, the mix of our products and services, supply and prices of raw materials and products, customer demand for our products and services, control of costs and expenses, our ability to obtain and maintain adequate intellectual property protection, our ability to successfully integrate acquired businesses, our ability to form and implement alliances, international growth, our compliance with governmental laws and regulations affecting our U.S. and international businesses including regulations of the U.S. Food and Drug Administration and foreign government regulators and tax obligations and risks, product liability and intellectual property litigation losses, reimbursement levels from third-party payors, cost-containment efforts of healthcare purchasing organizations, our ability to retain the independent agents and distributors who market our products, general industry and market conditions and growth rates and general domestic and international economic conditions including interest rate and currency exchange rate fluctuations. For a further list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Readers of this document are cautioned not to place undue reliance on these forward-looking statements, since, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this document.


'/>"/>
SOURCE Zimmer Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders
2. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2007 Results
3. Zimmer Announces Successful Completion of ORTHOsoft Takeover Bid
4. Zimmer Holdings to Present at Upcoming Investor Conferences
5. Ray Elliott to Retire as Chairman of Zimmer Holdings; John McGoldrick to Serve as Non-Executive Chairman
6. Zimmer Holdings Receives FDA Approval to Market Mobile Bearing Knee
7. Zimmer Holdings to Present at JPMorgan Healthcare Conference
8. Zimmer Holdings Announces Webcast and Conference Call of Fourth Quarter and Full-Year 2007 Results
9. Zimmer Spine Introduces New Rigid to Dynamic Stabilization Transition System
10. Zimmer Reports Fourth Quarter and 2007 Financial Results
11. Zimmer Holdings to Present at Merrill Lynch Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... On May 23rd during the National ... Science® and international water advocate, was honored by Ashram, Inc. as the world’s foremost ... who knelt on the banks of the Nile to fill their red clay pots ...
(Date:5/26/2016)... ... May 26, 2016 , ... Saint Francis ... several years, and the efforts have paid off. Since implementation of these ... of care to enhance perioperative patient experiences and reduce costly complications. Since implementation ...
(Date:5/26/2016)... Viejo, California (PRWEB) , ... May 26, 2016 , ... ... Transition Plugin for FCPX. , "This new layered style transition tool will ... said Christina Austion - CEO of Pixel Film Studios. , TranSweep is an ...
(Date:5/26/2016)... ... May 26, 2016 , ... TopConsumerReviews.com recently awarded their ... . , High blood pressure affects millions of people worldwide, and many patients ... lead to heart disease, stroke, kidney disease, and hardening of the arteries. However, ...
(Date:5/25/2016)... ... , ... The United States Food and Drug Administration (FDA) has now cleared ... To date, the company is the first and only manufacturer of low level laser ... androgenetic alopecia. , “This new level of clearance substantiates what many physicians have ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016 ... de doble terapia del mundo, introduce catéteres para ... OrbusNeich, una compañía global especializada en ... vidas, ha expandido su cartera incluyendo productos para ... JADE™ y Scoreflex™ PTA son los dispositivos de ...
(Date:5/24/2016)... 2016 Een app die artsen ... collectief patiënten kunnen behandelen, hun kennis kunnen delen en ... de nieuwe en revolutionaire MDLinking App, ontwikkeld door een ... dr. Hans Flu en oncologisch chirurg dr. Gijs ... is, wordt op dinsdag 24 mei officieel gepresenteerd op ...
(Date:5/23/2016)... ALBANY, New York , May 23, 2016 /PRNewswire/ ... new market report titled, " Exocrine Pancreatic Insufficiency Market ... Forecast 2013 - 2023 ." According to the report, ... at a CAGR of 8.3% from 2015 to 2023 ... pancreatic insufficiency (EPI) is a condition characterized by the ...
Breaking Medicine Technology: